280 related articles for article (PubMed ID: 135367)
21. [Changes in several blood coagulation parameters in the nephrotic syndrome].
Gasparotto ML; Bertoli M; Bertaglia E; Vertolli U; Varchetta V; Favaro P; Rebeschini M; Di Lavoro D; Romagnoli GF
Minerva Nefrol; 1981; 28(1):15-9. PubMed ID: 6793942
[No Abstract] [Full Text] [Related]
22. [Various fibrinolytic and coagulation characteristics of the blood plasma after contact with N-amyl alcohol].
Lussa A; Tymińska-Brzósko R
Rocz Akad Med Im Juliana Marchlewskiego Bialymst; 1979; 24():91-104. PubMed ID: 161647
[No Abstract] [Full Text] [Related]
23. Advances in clinical fibrinolysis.
Hessel LW; Kluft C
Clin Haematol; 1986 May; 15(2):443-63. PubMed ID: 2942332
[TBL] [Abstract][Full Text] [Related]
24. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
25. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
26. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].
Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F
Pol Tyg Lek; 1996 Feb; 51(6-9):91-3. PubMed ID: 8756741
[TBL] [Abstract][Full Text] [Related]
27. Human fibroblasts produce inhibitor directed against plasminogen activator when treated with glucocorticoids.
Crutchley DJ; Conanan LB; Maynard JR
Ann N Y Acad Sci; 1981; 370():609-16. PubMed ID: 6455956
[No Abstract] [Full Text] [Related]
28. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
[TBL] [Abstract][Full Text] [Related]
29. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
Veremeenko KN; Kizim AI
Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
[TBL] [Abstract][Full Text] [Related]
30. Fibrinolytic activity in coronary heart disease.
Yao SK; Chen ZJ; Tao SQ
Chin Med J (Engl); 1989 Sep; 102(9):660-3. PubMed ID: 2517077
[TBL] [Abstract][Full Text] [Related]
31. [Biological changes during the local administration of small doses of urokinase].
Michaud A; Aiach M; Fiessinger JN; Vayssairat M; Juillet Y
Nouv Presse Med; 1978 Oct; 7(35):3151. PubMed ID: 152910
[No Abstract] [Full Text] [Related]
32. Blocking of the fibrinolytic antiactivator by substituted benzoates.
Nanninga L; Guest M
Life Sci; 1974 Jun; 14(12):2507-11. PubMed ID: 4283613
[No Abstract] [Full Text] [Related]
33. The influence of the polyphenols of cider on plasmin and plasminogen activators.
Ogston D; Lea AG; Langhorne P; Wilson SB
Br J Haematol; 1985 Aug; 60(4):705-13. PubMed ID: 3161536
[TBL] [Abstract][Full Text] [Related]
34. [Fibrinolytic activity of the blood and synovial fluid in patients with rheumatoid arthritis].
Erov NK
Ter Arkh; 1986; 58(7):73-7. PubMed ID: 2945279
[TBL] [Abstract][Full Text] [Related]
35. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
Bachmann F
Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
[TBL] [Abstract][Full Text] [Related]
36. Alpha 2-antiplasmin, plasminogen activator inhibitor (PAI) and dilute blood clot lysis time in selected disease states.
Cucuianu M; Knauer O; Roman S
Thromb Haemost; 1991 Nov; 66(5):586-91. PubMed ID: 1725069
[TBL] [Abstract][Full Text] [Related]
37. Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis.
Glas-Greenwalt P; Kant KS; Dosekun A; Frazier J; Allen C; Pollak VE
J Lab Clin Med; 1985 Jan; 105(1):99-107. PubMed ID: 3871465
[TBL] [Abstract][Full Text] [Related]
38. Selected hemostatic abnormalities associated with neoplastic disease.
Ito R; Statland BE
Clin Lab Med; 1982 Sep; 2(3):599-625. PubMed ID: 6814812
[No Abstract] [Full Text] [Related]
39. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
[TBL] [Abstract][Full Text] [Related]
40. [Studies on the fibrinolytic therapy in the patients with nephrotic syndrome (author's transl)].
Shibata M; Shimizu K; Kishi T; Kobayashi K; Sakai H; Sugiyama H; Oguri M
Nihon Jinzo Gakkai Shi; 1980 Sep; 22(9):1197-207. PubMed ID: 6450847
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
